These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24679465)

  • 1. Commentary on "A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma." Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia.: BJU Int 2012;110(11 Pt B):E737-43. doi: 10.1111/j.1464-410X.2012.11550.x. [Epub 2012 Oct 29].
    Gottschalk A
    Urol Oncol; 2014 Apr; 32(3):374-5. PubMed ID: 24679465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma.
    Siva S; Pham D; Gill S; Corcoran NM; Foroudi F
    BJU Int; 2012 Dec; 110(11 Pt B):E737-43. PubMed ID: 23107102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
    Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
    Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
    Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
    Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
    Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
    Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.
    Kothari G; Foroudi F; Gill S; Corcoran NM; Siva S
    Acta Oncol; 2015 Feb; 54(2):148-57. PubMed ID: 25140860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
    Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
    Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
    Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.
    Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F
    Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
    Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
    J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU.
    Bentahila R; Bensalah K; Benziane-Ouaritini N; Barthelemy P; Rioux-Leclerc N; Correas JM; Belhomme S; Bigot P; Sargos P
    Fr J Urol; 2024 Jul; 34(7-8):102660. PubMed ID: 38823486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
    Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
    BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
    Pham D; Thompson A; Kron T; Foroudi F; Kolsky MS; Devereux T; Lim A; Siva S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1061-8. PubMed ID: 25442039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CyberKnife for inoperable renal tumors: Canadian pioneering experience.
    Nair VJ; Szanto J; Vandervoort E; Cagiannos I; Breau R; Malone C; Avruch L; Pantarotto J; Malone S
    Can J Urol; 2013 Oct; 20(5):6944-9. PubMed ID: 24128835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials.
    Ghia AJ; Chang EL; Bishop AJ; Pan HY; Boehling NS; Amini B; Allen PK; Li J; Rhines LD; Tannir NM; Tatsui CE; Brown PD; Yang JN
    J Neurosurg Spine; 2016 May; 24(5):829-36. PubMed ID: 26799117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative body radiotherapy for lung cancer.
    Franks KN; Jain P; Snee MP
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.